476 Comparing Beractant and Poractant Alfa for Treatment of Respiratory Distress in Premature Neonates

Background: Respiratory distress syndrome (RDS) is a major cause of mortality and morbidity in preterm infants. The aim of this study was to compare the complications of prematurity among preterm infants treated with two different natural surfactants. Materials and Methods: In a randomized clinical trial 150 preterm infants with RDS treated with exogenous surfactant were enrolled in the study. Group A consist of 79 neonates that received poractant (curosurf). Seventy one newborn infants in group B were treated with beractant (Survanta). Results: The mean gestational age for group A and B were 29.40±2.90 wk and 29.50±2.73 wk (P=0.82). The demographic and clinical variables were similar in both groups. The mean duration of intubation was significantly shorter in infants treated with poractant (3.13±1.80 vs. 4.06±2.7 days p=0.02). The mean duration of need for oxygen and hospitalization of patients in group A and B were 17.73±22.25 vs.19.14±17.85days (p=0.67) and 24.89±26.41 vs. 29.14±23.54 days (p= 0.32) respectively. There was no significant difference between groups with respect to mortality and morbidity including pulmonary hemorrhage, intraventricular hemorrhage (IVH), patent ductus arteriosus, sepsis, and bronchopulmonary dysplasia. Conclusions: In this study infants had received poractant had shorter duration of intubation than infants treated with beractant without difference in the duration of oxygen therapy or admission. There was no significant superiority of poractant over beractant.